AxoGen, Inc. (AXGN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $43.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality.
AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft (acellular nerve allograft), Axoguard Nerve Connector, Nerve Protector, Nerve Cap, and Avive+ Soft Tissue Matrix, primarily in the US. Avance Products represent... Read more
Sell if holding. Engine safety override at $43.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 96d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAvance Products60%10-K Item 1A: 'Approximately 60% of our total revenues are from sales of Avance Products'
- MEDIUMSupplierEvergen10-K Item 1A: 'Axoguard Nerve Connector and Axoguard Nerve Protector are only available through a distribution agreement with Evergen.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -13.2%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $43.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $40.06. Score 5.7/10, moderate confidence.
Take-profit target: $44.91 (+4.2% upside). Prior stop was $40.06. Stop-loss: $40.06.
Concentration risk — Product: Avance Products (60.0%); Target reached (-1.3% upside); Quality below floor (3.8 < 4.0).
AxoGen, Inc. trades at a P/E of N/A (forward 54.8). TrendMatrix value score: 4.8/10. Verdict: Sell.
16 analysts cover AXGN with a consensus score of 4.2/5. Average price target: $49.
What does AxoGen, Inc. do?AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft...
AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft (acellular nerve allograft), Axoguard Nerve Connector, Nerve Protector, Nerve Cap, and Avive+ Soft Tissue Matrix, primarily in the US. Avance Products represent approximately 60% of total revenues.